Zobrazeno 1 - 10
of 82
pro vyhledávání: '"J.R. Fitchett"'
Publikováno v:
International Journal of Infectious Diseases, Vol 21, Iss S1, p 232 (2014)
Externí odkaz:
https://doaj.org/article/4ca71a02413640ccb5e92feff8bbf195
Publikováno v:
International Journal of Infectious Diseases, Vol 21, Iss S1, p 396 (2014)
Externí odkaz:
https://doaj.org/article/7c7cd085d5eb4d379f16d6dcb461a90a
Autor:
J.R. Fitchett, Johnny E. Croy, Robin M Brown, Amita Datta-Mannan, Deepa Balasubramaniam, Aik Roy Heng, Jennifer Pereira
Publikováno v:
Biochemistry. 58:3116-3132
Interest in the development of bi- or multispecific antibody (BsAbs)-based biotherapeutics is growing rapidly due to their inherent ability to interact with many targets simultaneously, thereby potentially protracting their functionality relative to
Autor:
S.J. Demarest, Brian Kuhlman, Anton J. Frommelt, Xiufeng Wu, Deepa Balasubramaniam, Shawn Chang, Karen Froning, Heather Austin, F. Huang, Aik Roy Heng, J.R. Fitchett, Elaine M Conner, Mark T. Hilgers, Kenneth Weichert, Jessica Dong, Arlene Sereno, Jack Maguire
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression. Here, we use molecular modeling to identify mutations in th
Autor:
Jing Wang, Shaghayegh Morshedian, Joey P. Ting, Alfonso Espada, Carina Torres, Kai Zhang, Sayers Robert Owen, Priyanka Pandya, Howard B. Broughton, J.R. Fitchett, Juan J. Carrillo, Jim D. Durbin, Qing Zhang, Justine S. Cudal, Yuewei Qian, Feiyu F. Zhang, Sepideh Afshar
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0233961 (2020)
PLoS ONE, Vol 15, Iss 6, p e0233961 (2020)
Hundreds of target specific peptides are routinely discovered by peptide display platforms. However, due to the high cost of peptide synthesis only a limited number of peptides are chemically made for further analysis. Here we describe an accurate an
Autor:
Holly A. Bina, Bryan Edward Jones, Yan Ji, Jirong Lu, Victor J. Wroblewski, Robert J. Benschop, Qing Chai, Stacy Torgerson, Barrett Allan, James Nelson, Shane Atwell, Ningjie Hu, Chi-Kin Chow, Yu Tian, David K. Clawson, Mahmoud Ghanem, Barbra Barmettler, J.R. Fitchett, Joseph Manetta
Publikováno v:
MAbs
We describe a bispecific dual-antagonist antibody against human B cell activating factor (BAFF) and interleukin 17A (IL-17). An anti-IL-17 single-chain variable fragment (scFv) derived from ixekizumab (Taltz®) was fused via a glycine-rich linker to
Autor:
Amy L. Blount, Björn F. Lillemeier, Miriam Wolf, Christian Klammt, Dongyang T Li, Kai Zhang, J.R. Fitchett, Lucie Novotná
Publikováno v:
Nature Immunology. 16:961-969
Kinase recruitment to membrane receptors is essential for signal transduction. However, the underlying regulatory mechanisms are poorly understood. We investigated how conformational changes control T cell receptor (TCR) association and activity of t
Autor:
F. Huang, L. Gao, S.J. Demarest, Brian Kuhlman, Karen Froning, Kevin Houlihan, J.R. Fitchett, A. Pustilnik, S. Phan, Andrew Leaver-Fay, Xiufeng Wu, Jorg Hendle, Qing Chai, M. Bacica
Publikováno v:
Protein science : a publication of the Protein Society. 26(10)
The use of bispecific antibodies (BsAbs) to treat human diseases is on the rise. Increasingly complex and powerful therapeutic mechanisms made possible by BsAbs are spurring innovation of novel BsAb formats and methods for their production. The long-
Publikováno v:
Methods in Molecular Biology ISBN: 9781493968558
Glycoprofiling recombinant proteins expressed and secreted from mammalian cells is key to understanding their interactions with glycoprotein receptors in vivo. Recently, recombinant T cell receptors (TCRs) are being considered as therapeutic moieties
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd980e19b54dd4fa7021849d374c1a6e
https://doi.org/10.1007/978-1-4939-6857-2_12
https://doi.org/10.1007/978-1-4939-6857-2_12
Autor:
Michael Bacica, Stephen Demarest, Gavin C. Barnard, Yashas Rajendra, Robert B. Peery, Xiufeng Wu, J.R. Fitchett, Maria D. Hougland
Publikováno v:
Biotechnology progress. 33(2)
IgG bispecific antibodies (BsAbs) represent one of the preferred formats for bispecific antibody therapeutics due to their native-like IgG properties and their monovalent binding to each target. Most reported studies utilized transient expression in